Welcome to Leadenhall Capital Partners LLP,
a London based investment manager wholly focused on investing in insurance linked investments portfolios for institutional investors.
Leadenhall Capital Partners offers dedicated funds and managed accounts which give institutional investors access to both life and non-life insurance linked investments. Investors benefit from the attractive returns of the sector, whilst diversifying their risks from the traditional capital markets.
Many instruments, such as cat bonds and private placements of collateralised reinsurance, are used to transfer insurance linked risk to the capital markets. Leadenhall uses all of them to ensure liquidity, profitability, diversification and growth.
18 May 2017
Leadenhall is proud to have been recognised with the 2017 Trading Risk Award – “Life Transaction of the Year”. We regard this industry award as a testimony to our investment team’s continuing ability to structure innovative transactions and create added value to our investors. Below the official release made by Trading risk: “Leadenhall Capital Partners structured and invested in the $57.5mn Mekyi Funding deal for a sponsor that has not previously accessed capital from the ILS market. The notes provide Leadenhall investors with exposure to mortality trend risk, a diversifying risk to the mortality catastrophe, longevity and policy lapse exposures that make up the majority of life ILS investment opportunities. The transaction has a long maturity date but is structured to be tradable should a note holder wish to transfer it. It covered a specific pool of more than 500 lives.”
The promotion of hedge funds is restricted in some jurisdictions. In the UK, this is dependant on net worth and level of investment experience. US investors must meet the criteria to be accredited and qualified investors. Other jurisdictions have different requirements and you should check whether you are eligible to access promotional material.
If you are a qualified institutional investor interested in receiving information about our company and funds offering please contact:
Office: +44 (0)20 7746 1690
Mobile: +44 (0)77 2592 4836